Effect of captopril on infantile haemangiomas: A retrospective case series

Australasian Journal of Dermatology

Volumn 53, Issue 3, 2012, Pages 216-218

  Christou, Elizabeth M ^a   Wargon, Orli ^a  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

angiotensin I converting enzyme; captopril; haemangioma; hypertension; infantile haemangioma; prednisolone; treatment

Indexed keywords

ANTIBIOTIC AGENT; CAPTOPRIL; DEXCHLORPHENIRAMINE MALEATE; GAVISCON; OMEPRAZOLE; PREDNISOLONE; PROPRANOLOL; RANITIDINE; STEROID;

ARTICLE; CAPILLARY HEMANGIOMA; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFECT; FOLLOW UP; HUMAN; HYPERTENSION; MEDICAL RECORD REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; GLUCOCORTICOIDS; HEMANGIOMA; HUMANS; HYPERTENSION; INFANT; PREDNISOLONE; RETROSPECTIVE STUDIES;

EID: 84865113786     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2012.00901.x     Document Type: Article

References (11)

1. Itinteang T, Brasch HD, Tan ST, Day DJ,. Expression of components of the rennin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J. Plast. Reconstr. Aesthet. Surg. 2010; 64: 759-65.
2. Dickison P, Christou E, Wargon O,. A prospective study of infantile hemangiomas with a focus on incidence and risk factors. Pediatr. Dermatol. 2011; 28: 663-9.
3. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ,. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch. Dermatol. 2001; 137: 1208-13. (Pubitemid 32847844)
4. George ME, Sharma V, Jacobso J, Simon S, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch. Dermatol. 2004; 140: 963-9. (Pubitemid 39062647)
5. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, et al. Propranolol for severe hemangiomas of infancy. N. Engl. J. Med. 2008; 358: 2649-51. (Pubitemid 351831393)
6. Kim LH, Hogeling M, Wargon O, Jiwane A, et al. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J. Pediatr. Surg. 2011; 46: 759-63.
7. Hogeling M, Adams S, Wargon O,. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128: e259-66.
8. Ritter MR, Butschek RA, Friedlander M, Friedlander SF, Pathogenesis of infantile haemangioma: new molecular and cellular insights. Expert Rev. Mol. Med. 2007; 9: 1-19. (Pubitemid 351695558)
9. Khan ZA, Boscolo E, Picard A, Psutka S, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J. Clin. Invest. 2008; 118: 2592-9. (Pubitemid 351949786)
10. Storch CH, Hoeger P,. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br. J. Dermatol. 2010; 163: 269-74.
11. Itinteang T, Withers AHJ, Leadbitter P, Day DJ, et al. Pharmacologic therapies for infantile hemangioma: is there a rational basis? Plast. Reconstr. Surg. 2011; 128: 499-507.